IN2015DN01163A - - Google Patents
Info
- Publication number
- IN2015DN01163A IN2015DN01163A IN1163DEN2015A IN2015DN01163A IN 2015DN01163 A IN2015DN01163 A IN 2015DN01163A IN 1163DEN2015 A IN1163DEN2015 A IN 1163DEN2015A IN 2015DN01163 A IN2015DN01163 A IN 2015DN01163A
- Authority
- IN
- India
- Prior art keywords
- syndrome
- mediated
- disorder
- transportation
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698033P | 2012-09-07 | 2012-09-07 | |
| PCT/IB2013/058318 WO2014037900A1 (en) | 2012-09-07 | 2013-09-05 | Indole carboxamide derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01163A true IN2015DN01163A (enExample) | 2015-06-26 |
Family
ID=49585451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1163DEN2015 IN2015DN01163A (enExample) | 2012-09-07 | 2015-02-12 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9447039B2 (enExample) |
| EP (1) | EP2892880B1 (enExample) |
| JP (1) | JP6223452B2 (enExample) |
| KR (1) | KR20150048759A (enExample) |
| CN (1) | CN104603106B (enExample) |
| BR (1) | BR112015004666B1 (enExample) |
| CA (1) | CA2881351A1 (enExample) |
| EA (1) | EA028093B1 (enExample) |
| ES (1) | ES2660210T3 (enExample) |
| IN (1) | IN2015DN01163A (enExample) |
| WO (1) | WO2014037900A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106715417B (zh) | 2014-04-04 | 2020-01-14 | 爱欧梅特制药公司 | 药物中使用的吲哚衍生物 |
| US20170044100A1 (en) * | 2014-04-22 | 2017-02-16 | The Johns Hopkins University | Inhibitors of drug-resistant mycobacterium tuberculosis |
| LT3461821T (lt) * | 2014-10-24 | 2020-08-10 | Bristol-Myers Squibb Company | Indolo karboksamido junginiai, naudotini kaip kinazės inhibitoriai |
| CN107298650B (zh) * | 2016-04-15 | 2022-11-15 | 浙江中科创越药业有限公司 | 杂环羧酸酰胺配体及其在铜催化芳基卤代物偶联反应中的用途 |
| CN106085868B (zh) * | 2016-06-15 | 2019-07-12 | 中国医学科学院医药生物技术研究所 | 一株曲霉菌及其应用 |
| US10383848B2 (en) * | 2016-08-04 | 2019-08-20 | Creighton University | Indole-based therapeutics |
| US10858319B2 (en) | 2016-10-03 | 2020-12-08 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
| IL269210B2 (en) | 2017-03-10 | 2025-05-01 | Univ Rutgers | Indole derivatives as efflux pump inhibitors |
| WO2018165612A1 (en) | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| US11938114B2 (en) | 2017-03-10 | 2024-03-26 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| JP7281822B2 (ja) * | 2017-05-26 | 2023-05-26 | ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー | 細菌の排出ポンプ阻害剤 |
| US11458121B2 (en) | 2017-06-26 | 2022-10-04 | Rutgers, The State University Of New Jersey | Therapeutic compounds and methods to treat infection |
| EP3793976A4 (en) | 2018-05-17 | 2022-04-20 | Council of Scientific & Industrial Research | Indole compounds, process for the preparation and use thereof |
| KR102219563B1 (ko) * | 2019-02-15 | 2021-02-24 | 에스티팜 주식회사 | 페나진 유도체 제조를 위한 중간체 및 그의 제조방법 |
| JP2022549881A (ja) * | 2019-09-26 | 2022-11-29 | ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド | マイコバクテリア感染症の処置のためのチアゾールカルボキサミド化合物およびその使用 |
| CN110577483B (zh) * | 2019-09-26 | 2020-05-12 | 海南医学院 | 一种3,3-二取代-2-吲哚酮的绿色合成方法 |
| CN114746090A (zh) * | 2019-09-26 | 2022-07-12 | 结核病药物开发全球联盟公司 | 用于治疗分枝杆菌感染的氮杂吲哚甲酰胺化合物 |
| CA3151407A1 (en) * | 2019-09-26 | 2021-04-01 | Takushi Kaneko | Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections |
| RU2767542C1 (ru) * | 2021-05-24 | 2022-03-17 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Противотуберкулезное средство на основе 4-((гет)ароил)-3- гидрокси-1-(2-гидроксифенил)-5-(фенилтио)-1,5-дигидро-2Н-пиррол-2-онов |
| CN115583908B (zh) * | 2021-07-05 | 2024-08-06 | 西北农林科技大学 | 一种吲哚甲酰胺类化合物及其制备方法和用途 |
| US12012398B2 (en) * | 2021-07-12 | 2024-06-18 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
| WO2024118858A1 (en) * | 2022-12-02 | 2024-06-06 | Merck Sharp & Dohme Llc | Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
| CN118724763B (zh) * | 2024-09-02 | 2024-12-06 | 辽宁龙田化工科技有限公司 | 一种4-甲基苯磺酰氯合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US883049A (en) * | 1907-09-12 | 1908-03-24 | John W Piver | Tongue-and-groove joint for flooring. |
| FR2705095B1 (fr) * | 1993-05-12 | 1995-06-23 | Adir | Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| HU227197B1 (en) * | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| WO2003000657A1 (en) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| CA2464214C (en) | 2001-10-22 | 2011-02-08 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
| RU2004120784A (ru) | 2001-12-04 | 2005-08-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Замещенные 2-аминоциклоалканкарбоксамиды и их применение в качестве ингибиторов цистеиновой протеазы |
| US6759428B2 (en) | 2001-12-04 | 2004-07-06 | Roche Palo Alto Llc | Indole nitriles |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2003227360A1 (en) * | 2002-04-25 | 2003-11-10 | Yamanouchi Pharmaceutical Co., Ltd. | Novel amide derivatives or salts thereof |
| GB0428173D0 (en) * | 2004-12-23 | 2005-01-26 | Astrazeneca Ab | Compounds |
| US7825154B2 (en) * | 2005-08-12 | 2010-11-02 | The United States Of America As Represented By The Secretary Of The Army | Small molecule inhibitors of botulinum neurotoxins |
| EP3124489B1 (en) | 2006-04-04 | 2020-07-15 | Fibrogen, Inc. | Thiazolo-pyridine compounds as hif modulators |
| WO2009063495A2 (en) | 2007-09-20 | 2009-05-22 | Cadila Healthcare Limited | Substituted indole and its derivatives as cannabinoid modulators |
| PE20110819A1 (es) * | 2008-12-19 | 2011-11-02 | Bristol Myers Squibb Co | Compuestos de carbazol carboxamida utiles como inhibidores de cinasa |
| AP3069A (en) | 2009-02-27 | 2014-12-31 | Siga Technologies Inc | Thienopyridine derivatives for the treatment and prvention of dengue virus infection |
| TW201107330A (en) | 2009-07-31 | 2011-03-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| CA2781888C (en) | 2009-12-11 | 2019-06-18 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
| JP2012107001A (ja) * | 2010-10-22 | 2012-06-07 | Shionogi & Co Ltd | インドールアミド化合物を含有する医薬 |
| US9200046B2 (en) * | 2011-06-29 | 2015-12-01 | Cornell University | Reporter system for high throughput screening of compounds and uses thereof |
-
2013
- 2013-09-05 KR KR1020157005663A patent/KR20150048759A/ko not_active Withdrawn
- 2013-09-05 ES ES13792084.9T patent/ES2660210T3/es active Active
- 2013-09-05 EA EA201590504A patent/EA028093B1/ru not_active IP Right Cessation
- 2013-09-05 CA CA2881351A patent/CA2881351A1/en not_active Abandoned
- 2013-09-05 JP JP2015530536A patent/JP6223452B2/ja not_active Expired - Fee Related
- 2013-09-05 BR BR112015004666-5A patent/BR112015004666B1/pt not_active IP Right Cessation
- 2013-09-05 US US14/420,074 patent/US9447039B2/en active Active
- 2013-09-05 CN CN201380046508.9A patent/CN104603106B/zh not_active Expired - Fee Related
- 2013-09-05 WO PCT/IB2013/058318 patent/WO2014037900A1/en not_active Ceased
- 2013-09-05 EP EP13792084.9A patent/EP2892880B1/en not_active Not-in-force
-
2015
- 2015-02-12 IN IN1163DEN2015 patent/IN2015DN01163A/en unknown
-
2016
- 2016-08-19 US US15/242,160 patent/US20160355477A1/en not_active Abandoned
-
2020
- 2020-06-12 US US16/899,931 patent/US20210032202A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104603106A (zh) | 2015-05-06 |
| AU2013311235B2 (en) | 2016-03-24 |
| EA028093B1 (ru) | 2017-10-31 |
| CA2881351A1 (en) | 2014-03-13 |
| ES2660210T3 (es) | 2018-03-21 |
| BR112015004666A2 (pt) | 2017-07-04 |
| EA201590504A1 (ru) | 2015-07-30 |
| EP2892880B1 (en) | 2017-11-22 |
| JP2015527388A (ja) | 2015-09-17 |
| US20160355477A1 (en) | 2016-12-08 |
| US20150175539A1 (en) | 2015-06-25 |
| AU2013311235A1 (en) | 2015-02-26 |
| EP2892880A1 (en) | 2015-07-15 |
| WO2014037900A1 (en) | 2014-03-13 |
| JP6223452B2 (ja) | 2017-11-01 |
| KR20150048759A (ko) | 2015-05-07 |
| US20210032202A1 (en) | 2021-02-04 |
| BR112015004666B1 (pt) | 2022-04-26 |
| CN104603106B (zh) | 2017-05-10 |
| US9447039B2 (en) | 2016-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN01163A (enExample) | ||
| EA201591527A1 (ru) | Новые производные пиридина | |
| PH12015501083A1 (en) | Novel pyridine derivatives | |
| MX2015015412A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| MX350539B (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. | |
| MY176814A (en) | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | |
| MY182328A (en) | Pyridine-2-amides useful as cb2 agonists | |
| MY179412A (en) | Pyridine-2-amides useful as cb2 agonists | |
| EA201291317A1 (ru) | Тетрагидропиридопиримидиновые производные | |
| PH12015501933A1 (en) | Novel pyridine derivatives | |
| PH12015501843A1 (en) | Novel pyrazol derivatives | |
| MX349373B (es) | Nuevos derivados de pirazina. | |
| MY178390A (en) | Inhibitors of iap | |
| MY180050A (en) | Novel purine derivatives | |
| MX2014008918A (es) | Nuevos derivados de pirrolidina. | |
| MX363458B (es) | Nuevos derivados de tetrazolona. | |
| PH12015500262A1 (en) | Novel pyridine derivatives | |
| MX351093B (es) | Nuevos derivados de azetidina. | |
| IN2015DN02513A (enExample) | ||
| MX2016004333A (es) | Uso de odiparcil en el tratamiento de una mucopolisacaridosis. |